Chinese chemical suppliers link peptide sales to fentanyl precursor networks

Chinese chemical suppliers are increasingly blending peptides with fentanyl precursors in their online catalogs, often promoting both openly. These vendors, long identified by U.S. authorities as sources of fentanyl precursors, now prominently feature peptides like semaglutide and Melanotan II alongside dangerous chemicals used in opioid production. Crypto payments to these suppliers surged from USD 28.2 million in 2023 to USD 37.3 million in 2025, with most transactions shifting from Bitcoin to USDT on TRON.

The U.S. stands as the largest identifiable source of buyer funds, accounting for 60% of traceable payments. This trend underscores a growing concern: Americans seeking weight-loss peptides or other unregulated compounds may unwittingly be funding operations tied to fentanyl trafficking. The dual nature of these suppliers, selling both legal-sounding peptides and illegal precursors, has raised alarms among law enforcement and compliance teams.

While some vendors have obscured fentanyl precursor listings following DOJ charges and Treasury sanctions, TRM Labs' analysis reveals that many continue to sell both product types concurrently. The U.S. government has taken steps to curb this activity, including indictments and terrorism financing charges against Chinese suppliers. Yet crypto inflows have continued to rise, highlighting the challenge of regulating this shadowy market.

For consumers, the risks extend beyond health concerns tied to unregulated peptides. Their purchases could inadvertently support networks supplying fentanyl precursors to drug trafficking organizations. Crypto businesses face a growing compliance challenge as these vendors expand their reach through retail customer payments, often routed via consumer payment apps rather than traditional exchanges.